CME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CME Group Inc is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial performance and growth, the lack of significant trading signals, cautious analyst sentiment, and recent congress trading data indicating selling activity suggest a more cautious approach. The stock's price trend and technical indicators are neutral, and options data reflects bearish sentiment. Waiting for a clearer entry signal or more favorable conditions may be prudent.
The technical indicators are mixed. The MACD is positive but contracting, RSI is neutral at 52.024, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 316.361, with resistance at 326.492 and support at 306.23. The overall trend is neutral to slightly bullish.
Record average daily trading volume of 37.6 million contracts in February, reflecting strong market demand.
Strong financial performance in Q4 2025, with revenue up 26.71% YoY and net income up 35.23% YoY.
Positive analyst upgrades, including Erste Group upgrading to Buy on March 5, 2026.
Recent congress trading data shows 4 sale transactions and no purchases, indicating cautious sentiment.
Downgrade by Argus on March 4, 2026, citing muted growth in key segments.
Options data reflects bearish sentiment with high put-call ratios.
Neutral insider and hedge fund trading trends.
CME Group reported strong Q4 2025 financials: Revenue increased 26.71% YoY to $3.12 billion, net income increased 35.23% YoY to $1.17 billion, and EPS grew 35% YoY to $3.24. This demonstrates robust growth and profitability.
Analyst sentiment is mixed. Recent upgrades include Erste Group upgrading to Buy, while Argus downgraded to Hold citing muted growth in certain segments. Price targets range from $232 (BofA) to $340 (Morgan Stanley), with a median target near $310, close to the current price.
